Egbert F Smit
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort
Gautschi O, Kerjouan M, Michels S, Pall G, Rothschild S, Schmid-Bindert G, Scheffler M, Veillon R, Wannesson L, Diebold J, Zalcman G, Filleron T, Huret B, Curioni-Fontecedro A, Milia J, Cabarrou B, Bluthgen M, Besse B, Smit E, Wolf J, Peters S, Früh M, Koeberle D, Oulkhouir Y, Schuler M, Mazières J. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort. J Thorac Oncol 2015; 10:1451-7.
01.10.2015Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort
01.10.2015J Thorac Oncol 2015; 10:1451-7
Gautschi Oliver, Kerjouan Mallorie, Michels Sebastian, Pall Georg, Rothschild Sacha, Schmid-Bindert Gerald, Scheffler Matthias, Veillon Rémi, Wannesson Luciano, Diebold Joachim, Zalcman Gérard, Filleron Thomas, Huret Benjamin, Curioni-Fontecedro Alessandra, Milia Julie, Cabarrou Bastien, Bluthgen Marie-Virginia, Besse Benjamin, Smit Egbert F, Wolf Juergen, Peters Solange, Früh Martin, Koeberle Dieter, Oulkhouir Youssouf, Schuler Martin, Mazières Julien
Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study
Jörger M, Beijnen J, Huitema A, Vincent A, Smits P, Doodeman V, Bard M, Haitjema T, Smit E, Baas P, Burgers S, Schellens J. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer 2011; 118:2466-75.
28.09.2011Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study
28.09.2011Cancer 2011; 118:2466-75
Jörger Markus, Beijnen Jos H, Huitema Alwin D R, Vincent Andrew, Smits Paul H M, Doodeman Valerie D, Bard Martin P L, Haitjema Tjeerd J, Smit Egbert F, Baas Paul, Burgers Sjaak A, Schellens Jan H M
Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?
Buikhuisen W, Burgers J, Vincent A, Schellens J, Beijnen J, Smit E, Jörger M. Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?. J Clin Oncol 2010; 28:e482-3; author reply e484.
06.07.2010Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?
06.07.2010J Clin Oncol 2010; 28:e482-3; author reply e484
Buikhuisen Wieneke A, Burgers Jacobus A, Vincent Andrew D, Schellens Jan H M, Beijnen Jos H, Smit Egbert F, Jörger Markus
Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer
Smit E, van Zandwijk N, Vincent A, Schellens J, Jörger M, Dingemans A, Eppinga P, Smit H, Biesma B, Burgers S, Groen H. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009; 27:2038-45.
20.04.2009Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer
20.04.2009Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009; 27:2038-45
Smit Egbert F, van Zandwijk Nico, Vincent Andrew, Schellens Jan H, Jörger Markus, Dingemans Anne-Marie C, Eppinga Pier, Smit Hans J M, Biesma Bonne, Burgers Sjaak A, Groen Harry J M